Bacteroides xylanisolvens as Next Generation Probiotics
Preclinical trials have shown that Bacteroides are widely recognized as new beneficial candidates for reducing inflammation by regulating lymphocyte and cytokine expression, controlling metabolism, and preventing cancer. In addition, the European Commission has for the first time approved the use of Bacteroides xylanisolvens (B. xylanisolvens) in food, opening the door to further investigation and application of this promising flora. Creative Biolabs focuses on the development of live biotherapeutic products (LBP) and has deep experience in the research of potential probiotics.
Introduction of B. xylanisolvens
B. xylanisolvens is among a few Bacteriodetes species that has been also considered a next generation therapeutic. This species was isolated from feces and was able to degrade xylan to short-chain fatty acids including acetate, succinate, and propionate. Some Bacteroides species in the family Bacteroidaceae include B ovatus, B. xylanisolvens, B. uniformis are critical species for inducing intestinal IgA production, which acted as a protective factor to maintain the stability of the intestinal environment by limiting bacterial and endotoxin invasion of intestinal epithelial cells, promoting bacterial clearance, and regulating bacterial colonization. B. xylanisolvens has also been considered a next generation probiotic (NGP). It does not encode the B. fragilis enterotoxin or produce PSA.
B. xylanisolvens for Disease Treatment
A study using heat-inactivated cells showed that oral supplementation of B. xylanisolvens increased the level of TFa-specific immunoglobulin M serum antibody in a dose-dependent manner. Since reduced levels of TFα-specific IgM antibodies have been observed in cancer, the researchers speculated that B. xylanisolvens may reduce the risk of cancer development through the cancer immune surveillance system. It is important to note that this beneficial effect was observed in inactivated cells, while the effect on live bacteria is unknown.
The gut microbiota has been proposed as a target for drug design against NAFLD. Oral treatment with Ganoderma meroterpene derivative (GMD) effectively alleviated hyperlipidemia and steatohepatitis, improved glucose tolerance, and modulated gut microbiota in HFD-fed fa/fa rats. The enriched gut symbionts B. xylanisolvens, B. thetaiotaomicron, B. dorei, and B. uniformis by GMD contributed to the increased gut folate and the subsequent enhancement of folate-dependent one-carbon metabolisms that mediated the beneficial effects of GMD. Tests with live, heat-killed, and folate-synthesis-deficient B. xylanisolvens strains demonstrated the microbial folate-dependent anti-NAFLD effects of B. xylanisolvens. Administration of live B. xylanisolvens reduces hepatic steatosis and enhances the folate-mediated signaling pathways in mice. This work confirms the therapeutic potential of GMD and B. xylanisolvens in alleviating NAFLD and provides insights into the therapeutic mechanism targeting the gut microbiota.
What Services Can We Provide for B. xylanisolvens at Creative Biolabs?
B. xylanisolvens Related Products at Creative Biolabs
We supply a variety of B. xylanisolvens strains of different preservation numbers.
-
Customized strain culture supernatant. (e.g.: for animal research)
-
Customized strain lyophilized powder containing certain CFU. (e.g.: for animal research)
Devoted to providing professional and well-tailored custom services for more than 10 years, Creative Biolabs has gained a global reputation for assisting numerous customers with outstanding customer assistance. Our goal is to provide our customers with affordable development services with reliable results. If you are interested in our B. xylanisolvens related services and products, please contact us for further information.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
